External submission request from Merck and Co.:
Recommend the addition of pembrolizumab as a third-line systemic treatment for recurrent, locally advanced or metastatic gastroesophageal junction adenocarcinoma whose tumors express PD-L1 as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy.

Based on a review of the data, the panel consensus was to add "Pembrolizumab for third-line or subsequent therapy for PD-L1 positive esophageal and EGJ adenocarcinoma" under "Other Regimens" for "Second-line or Subsequent Therapy" options to treat unresectable, locally advanced, recurrent, or metastatic disease (where local therapy is not indicated)." A corresponding footnote was added that states, "Pembrolizumab is approved for patients with EGJ adenocarcinoma with PD-L1 expression levels ≥ 1 as determined by an FDA-approved test. The NCCN Panel recommends that the pembrolizumab treatment option be extended to patients with esophageal, in addition to EGJ, adenocarcinomas with PD-L1 expression levels ≥ 1."